Trials / Completed
CompletedNCT00402532
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Hannover Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Initial dosage 2 x 0.75 mg/d |
| DRUG | Mycophenolatmofetil | Initial dosage 2 x 500 mg/d intravenous |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2011-11-01
- Completion
- 2011-12-01
- First posted
- 2006-11-22
- Last updated
- 2011-12-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00402532. Inclusion in this directory is not an endorsement.